ENDRA Life Sciences Inc. (NDRA)
Nasdaq · Healthcare · Diagnostics & Research
$6.31+4.13%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $9.5M
- 52-week range
- $2.96 – $9.85
- 52-week change
- −2.42%
- EPS (trailing)
- −$6.26
Fiscal year to Dec 2025
- Net income
- −$7.0M
- Diluted EPS
- −$8.93
- Free cash flow
- −$5.2M
From the company’s annual report on SEC EDGAR.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Headquarters: Ann Arbor, United States · 9 employees · endrainc.com